UPCOMING SESSIONS in ET
Fri, Nov 20, 2026
6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness Hamide Eygoren Register
UPCOMING SESSIONS in ET
Fri, Nov 20, 2026 · 6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness
Hamide Eygoren
Register
View all sessions

Recognizing the Overlooked: A Pharmacist's Guide to Early Detection and Diagnostic Optimization in Transthyretin Amyloidosis Cardiomyopathy

Key Information
summary/abstract

Program Information
 

Transthyretin amyloidosis cardiomyopathy (ATTR-CM) carries a substantial and historically underestimated clinical burden, especially among patients with heart failure with preserved ejection fraction (HFpEF). Due to its overlapping presentation with HFpEF and other cardiovascular conditions, ATTR-CM remains frequently underrecognized and undiagnosed. Compounding this challenge is that patients with ATTR-CM may have suboptimal responses to standard heart failure therapies, which can serve as an important clinical clue warranting further evaluation. Early detection of ATTR-CM is paramount, as disease-modifying therapies (DMTs) demonstrate the greatest benefit when initiated in earlier stages. Although the American College of Cardiology released a Concise Clinical Guidance report on the evaluation and management of ATTR-CM, alongside the ACC Expert Consensus Decision Pathway and the AHA Scientific Statement on its evolving diagnosis and management, evidence suggests that these recommendations are not being integrated routinely into clinical decision-making. This session will equip pharmacists to recognize ATTR-CM pathophysiology to facilitate timely diagnostic workups. Faculty will outline the expanding treatment landscape, while emphasizing the pharmacist’s pivotal role across the care continuum including navigating specialty pharmacy distribution, managing drug interactions and medication use, treatment adjustment based on relevant laboratory values, and delivering patient-centered counseling.